- Home
- SISI vs HOTH Comparison
SISI vs HOTH Comparison
Compare SISI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- HOTH
- Stock Information
- Founded
- SISI 1997
- HOTH 2017
- Country
- SISI China
- HOTH United States
- Employees
- SISI N/A
- HOTH N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- HOTH Health Care
- Exchange
- SISI Nasdaq
- HOTH Nasdaq
- Market Cap
- SISI 14.9M
- HOTH 8.3M
- IPO Year
- SISI 2016
- HOTH 2019
- Fundamental
- Price
- SISI $0.17
- HOTH $1.42
- Analyst Decision
- SISI
- HOTH Strong Buy
- Analyst Count
- SISI 0
- HOTH 3
- Target Price
- SISI N/A
- HOTH $4.00
- AVG Volume (30 Days)
- SISI 3.5M
- HOTH 809.7K
- Earning Date
- SISI 05-15-2025
- HOTH 05-12-2025
- Dividend Yield
- SISI N/A
- HOTH N/A
- EPS Growth
- SISI N/A
- HOTH N/A
- EPS
- SISI N/A
- HOTH N/A
- Revenue
- SISI $9,601,324.00
- HOTH N/A
- Revenue This Year
- SISI N/A
- HOTH N/A
- Revenue Next Year
- SISI N/A
- HOTH N/A
- P/E Ratio
- SISI N/A
- HOTH N/A
- Revenue Growth
- SISI 1133.26
- HOTH N/A
- 52 Week Low
- SISI $0.15
- HOTH $0.58
- 52 Week High
- SISI $117.65
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- SISI 27.89
- HOTH 64.74
- Support Level
- SISI $0.15
- HOTH $1.17
- Resistance Level
- SISI $0.23
- HOTH $1.34
- Average True Range (ATR)
- SISI 0.03
- HOTH 0.10
- MACD
- SISI 0.01
- HOTH 0.00
- Stochastic Oscillator
- SISI 7.49
- HOTH 94.32
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.